BTIG downgraded Keros Therapeutics (KROS) to Neutral from Buy after dosing in higher dose cohorts of the TROPOS study was halted due to adverse events. Following the news, the firm thinks the differentiation opportunity for bleeding events/telangiectasias could end up taking real world safety data to convince most and expects the FDA to “be inclined to take a conservatively categorical approach” to labeling regarding these risks.
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KROS:
- Morning Movers: Keros Therapeutics plummets after halting TROPOS trial dosing
- Keros Therapeutics provides update on Phase 2 TROPOS trial
- Keros Therapeutics presents clinical data from Elritercept program at ASH
- Keros Therapeutics management to meet with Oppenheimer
- Takeda, Keros Therapeutics enter exclusive elritercept license agreement